Cargando…
ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
BACKGROUND: Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels of current neuroendocrine markers exhibit high case-...
Autores principales: | Shen, Michelle, Liu, Shiqin, Toland, Angus, Hsu, En-Chi, Hartono, Alifiani B., Alabi, Busola R., Aslan, Merve, Nguyen, Holly M., Sessions, Conner J., Nolley, Rosalie, Shi, Chanjuan, Huang, Jiaoti, Brooks, James D., Corey, Eva, Stoyanova, Tanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667239/ https://www.ncbi.nlm.nih.gov/pubmed/37798372 http://dx.doi.org/10.1038/s41416-023-02448-y |
Ejemplares similares
-
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
por: Hsu, En-Chi, et al.
Publicado: (2021) -
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
por: Liu, Shiqin, et al.
Publicado: (2021) -
Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay
por: Aslan, Merve, et al.
Publicado: (2021) -
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020) -
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
por: Liu, Shiqin, et al.
Publicado: (2020)